Article Text

Download PDFPDF
Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis
  1. Hiroki Masuda,
  2. Masahiro Mori,
  3. Satoshi Kuwabara
  1. Neurology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan
  1. Correspondence to Dr Hiroki Masuda, Neurology, Chiba University Graduate School of Medicine School of Medicine, Chiba, Japan; hiroki_masuda{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Alemtuzumab therapy may facilitate remyelination in patients with multiple sclerosis

Multiple sclerosis (MS) is a demyelinating, inflammatory and potentially degenerative disorder of the central nervous system. Whereas, an initial event triggers immune-mediated demyelination in MS, in the secondary progressive phase, axonal degeneration is thought to be due to impaired axo-glial interaction, which leads to a gradual worsening of the disability. In the development of an efficient therapeutic strategy for MS, stimulating or enhancing remyelination is important because remyelination leads to improvement in impulse transmission and metabolic support to the underlying axon.1 Clemastine fumarate and opicinumab, which both target remyelination, have been reported to show reduced visual evoked potentials (VEP) latency in patients with MS and optic neuritis, …

View Full Text


  • Contributors HM drafted the text, and MM and SK supervised and made revisions.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles